CRSP vs. BEAM

Last updated Apr 2, 2026

Compare and contrast key facts about CRISPR Therapeutics AG (CRSP) and Beam Therapeutics Inc. (BEAM).

Performance

CRSP vs. BEAM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in CRISPR Therapeutics AG (CRSP) and Beam Therapeutics Inc. (BEAM). The values are adjusted to include any dividend payments, if applicable.

CRSP vs. BEAM - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
CRSP CRISPR Therapeutics AG	-6.92%	33.23%	-37.12%	54.00%	-46.36%	-50.51%	181.81%
BEAM Beam Therapeutics Inc.	-12.63%	11.77%	-8.89%	-30.40%	-50.92%	-2.39%	335.41%

Fundamentals

EPS CRSP : -$5.47 BEAM : -$0.78
PS Ratio CRSP : 118.44 BEAM : 97.47
Total Revenue (TTM) CRSP : $36.75M BEAM : $25.63M
Gross Profit (TTM) CRSP : -$130.60M BEAM : -$284.71M
EBITDA (TTM) CRSP : -$529.50M BEAM : -$352.98M

Returns By Period

In the year-to-date period, CRSP achieves a -6.92% return, which is significantly higher than BEAM's -12.63% return.

CRSP

• 1D: 2.61%
• 1M: -19.68%
• YTD: -6.92%
• 6M: -26.22%
• 1Y: 47.28%
• 3Y*: 2.57%
• 5Y*: -16.38%
• 10Y*: —

BEAM

• 1D: 1.64%
• 1M: -15.58%
• YTD: -12.63%
• 6M: 0.37%
• 1Y: 37.34%
• 3Y*: -7.52%
• 5Y*: -21.20%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

CRSP vs. BEAM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CRSP

CRSP Risk / Return Rank: 64
CRSP Sharpe Ratio Rank: 66
CRSP Sortino Ratio Rank: 67
CRSP Omega Ratio Rank: 62
CRSP Calmar Ratio Rank: 63
CRSP Martin Ratio Rank: 60

BEAM

BEAM Risk / Return Rank: 58
BEAM Sharpe Ratio Rank: 58
BEAM Sortino Ratio Rank: 62
BEAM Omega Ratio Rank: 58
BEAM Calmar Ratio Rank: 56
BEAM Martin Ratio Rank: 55

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CRSP vs. BEAM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for CRISPR Therapeutics AG (CRSP) and Beam Therapeutics Inc. (BEAM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CRSP	BEAM	Difference
Sharpe ratio Return per unit of total volatility	0.75	0.49	+0.26
Sortino ratio Return per unit of downside risk	1.50	1.30	+0.20
Omega ratio Gain probability vs. loss probability	1.17	1.15	+0.02
Calmar ratio Return relative to maximum drawdown	1.03	0.63	+0.40
Martin ratio Return relative to average drawdown	2.03	1.39	+0.64
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

CRSP vs. BEAM - Sharpe Ratio Comparison

The current CRSP Sharpe Ratio is 0.75, which is higher than the BEAM Sharpe Ratio of 0.49. The chart below compares the historical Sharpe Ratios of CRSP and BEAM, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	CRSP	BEAM	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.75	0.49	+0.26
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.27	-0.28	+0.01
Sharpe Ratio (All Time) Calculated using the full available price history	0.22	0.05	+0.17

Correlation

The correlation between CRSP and BEAM is 0.70, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

CRSP vs. BEAM - Dividend Comparison

Neither CRSP nor BEAM has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

CRSP vs. BEAM - Drawdown Comparison

The maximum CRSP drawdown since its inception was -85.11%, roughly equal to the maximum BEAM drawdown of -89.12%. Use the drawdown chart below to compare losses from any high point for CRSP and BEAM.

Drawdown Indicators

	CRSP	BEAM	Difference
Max Drawdown Largest peak-to-trough decline	-85.11%	-89.12%	+4.01%
Max Drawdown (1Y) Largest decline over 1 year	-42.25%	-38.15%	-4.10%
Max Drawdown (5Y) Largest decline over 5 years	-80.68%	-89.12%	+8.44%
Current Drawdown Current decline from peak	-76.76%	-81.87%	+5.11%
Average Drawdown Average peak-to-trough decline	-48.71%	-59.31%	+10.60%
Ulcer Index Depth and duration of drawdowns from previous peaks	21.35%	17.25%	+4.10%

Volatility

CRSP vs. BEAM - Volatility Comparison

CRISPR Therapeutics AG (CRSP) and Beam Therapeutics Inc. (BEAM) have volatilities of 18.14% and 17.48%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CRSP	BEAM	Difference
Volatility (1M) Calculated over the trailing 1-month period	18.14%	17.48%	+0.66%
Volatility (6M) Calculated over the trailing 6-month period	44.91%	53.97%	-9.06%
Volatility (1Y) Calculated over the trailing 1-year period	63.81%	77.28%	-13.47%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	60.36%	75.45%	-15.09%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	64.42%	80.54%	-16.12%

Financials